Bellicum Pharmaceuticals - BLCM Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLCM shares.
View BLCM analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 12-month target prices for Bellicum Pharmaceuticals' shares. Their BLCM share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 420.8% from the stock's current price.
View analysts price targets for BLCM or view top-rated stocks among Wall Street analysts.

Bellicum Pharmaceuticals' stock was trading at $1.49 at the beginning of 2022. Since then, BLCM shares have decreased by 35.6% and is now trading at $0.96.
View the best growth stocks for 2022 here.

Bellicum Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 129,300 shares, a decrease of 7.1% from the October 31st total of 139,200 shares. Based on an average daily volume of 14,300 shares, the days-to-cover ratio is presently 9.0 days.
View Bellicum Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our BLCM earnings forecast.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) posted its earnings results on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $1.15. The biopharmaceutical company had revenue of $0.70 million for the quarter.

Bellicum Pharmaceuticals shares reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), TransEnterix (TRXC), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

(BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLCM stock can currently be purchased for approximately $0.96.

Bellicum Pharmaceuticals (NASDAQ:BLCM) has a market capitalization of $8.27 million and generates $6.20 million in revenue each year. The biopharmaceutical company earns $-9,700,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The official website for the company is www.bellicum.com. The biopharmaceutical company can be reached via phone at (832) 384-1100 or via email at robert.uhl@westwicke.com.